Uveitis management has made a dramatic progress in the last decade with the development of new drugs as well as the change in the approach to the patients. There are several new drugs available including biologics, recombinant monoclonal antibodies against interleukins including IL-17, IL-l, and IL-6, and anti-TNF-and T-cell inhibitors such as fusion proteins. In addition, there has been a shift in the drug administration with the preference of local administration of therapy by using intravitreal injection or iontophoresis. The widespread use of anti-VegF agents has brought a change in the management strategies of inflammatory choroidal neovascular membranes as well as uveitic macular edema. The availability of newer imaging techniques including fundus autofluorescence (FAF) for imaging of the retinal pigment epithelium and enhanced depth imaging of the choroid by OCT too has influenced the management of uveitis by titrating the therapy for each patient.
This special issue on update in uveitis management has review articles as well as original articles addressing these issues. We sincerely hope that the readers will find these wellselected manuscripts of interest and obtain useful information to get an update on the management of uveitis.
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